Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings

Core Insights - Nuwellis, Inc. has reinforced its leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload through new real-world data presented at the 2025 ASN Kidney Week [1][2] Group 1: Study Findings - A retrospective analysis reviewed 69 cases treated with Aquadex from 2018 to 2024, demonstrating effective fluid removal in patients with various underlying conditions [2] - The analysis revealed an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among patients on vasopressor support [3] - The study emphasizes that Aquadex can be safely applied across a wide range of complex patients, aiding clinicians in achieving euvolemia when other measures are insufficient [4] Group 2: Clinical Relevance - The findings support precision ultrafiltration as a complement to traditional kidney replacement therapy, with moderate and individualized ultrafiltration rates linked to improved outcomes in critically ill patients [5] - Aquapheresis is increasingly relevant in nephrology and critical care, where controlled fluid removal can stabilize hemodynamics and support renal recovery [6] - The study reflects a shift in fluid management practices, highlighting its importance as a vital sign of patient stability [7] Group 3: Company Overview - Nuwellis, Inc. is dedicated to advancing cardio-renal care by enabling earlier, safer, and more controlled fluid management for patients [8] - The Aquadex SmartFlow system is designed for ultrafiltration therapy, indicated for patients with fluid overload unresponsive to medical management [9]